Clark C P, Peters G N, O'Brien K M
Department of Surgery, Baylor University Medical Center, Dallas, Texas 75246.
Cancer. 1993 Oct 1;72(7):2170-4. doi: 10.1002/1097-0142(19931001)72:7<2170::aid-cncr2820720717>3.0.co;2-1.
The stage of breast cancer at diagnosis in women who have undergone augmentation mammoplasty has been examined with conflicting results. Additional evaluation of this population is needed.
A retrospective review of a large cancer center's breast cancer registry for a 116-month period was performed. Comparisons of patient age, method of detection, and pathologic stage of disease at presentation were performed for 33 patients with augmented breasts and 1735 patients with nonaugmented breasts who were treated.
Twenty-four percent of the patients with augmented breasts and 42% of those with nonaugmented breasts had mammographically detected cancers (P = NS). The incidence of ductal carcinoma in situ in the two groups was similar (18% versus 15%). Sizes of the mammographically detected tumors in the two groups were comparable; however, palpable tumors in the augmented group were significantly smaller than were those in the nonaugmented group. Overall, a significant difference in axillary lymph node involvement was detected, with 19% of the augmented group and 41% of the nonaugmented group having positive lymph nodes. In patients with palpable tumors, axillary lymph node involvement also was significantly different, with 22% of the patients with augmented breasts and 58% of those with nonaugmented breasts having axillary lymph node metastases. In the mammographically detected tumors, there was no significant difference in axillary lymph node metastases between the patients with augmented (13%) and those with nonaugmented (15%) breasts.
Early detection of breast cancer is possible in the patient who has undergone augumentation mammoplasty. Mammography was successful in detecting occult lesions, and palpation detected smaller tumors. In this cohort, there was no evidence to suggest that the patients with augmented breasts had more advanced disease at presentation.
对于接受过隆乳术的女性，其乳腺癌诊断时的分期情况已有研究，但结果存在矛盾。该人群仍需进一步评估。
对一家大型癌症中心116个月期间的乳腺癌登记资料进行回顾性分析。比较了33例隆乳患者和1735例未隆乳患者的年龄、检测方法及疾病初诊时的病理分期。
24%的隆乳患者和42%的未隆乳患者通过乳房X线检查发现癌症（P=无显著性差异）。两组导管原位癌的发生率相似（分别为18%和15%）。两组乳房X线检查发现的肿瘤大小相当；然而，隆乳组可触及的肿瘤明显小于未隆乳组。总体而言，腋窝淋巴结受累情况存在显著差异，隆乳组19%有阳性淋巴结，未隆乳组为41%。在可触及肿瘤的患者中，腋窝淋巴结受累情况也有显著差异，隆乳患者中有22%发生腋窝淋巴结转移，未隆乳患者中这一比例为58%。在乳房X线检查发现的肿瘤中，隆乳患者（13%）和未隆乳患者（15%）腋窝淋巴结转移情况无显著差异。
接受过隆乳术的患者有可能实现乳腺癌的早期检测。乳房X线检查成功检测出隐匿性病变，触诊发现的肿瘤较小。在该队列中，没有证据表明隆乳患者在初诊时疾病进展更严重。
